Literature DB >> 10750554

Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene.

B L Langdahl1, E Løkke, M Carstens, L L Stenkjaer, E F Eriksen.   

Abstract

Interleukin-1beta (IL-1beta) is a potent stimulator of bone resorption, and has been implicated in the pathogenesis of high bone turnover and osteoporosis. IL-1 receptor antagonist (IL-1ra) is a competitive inhibitor of IL-1beta effects and the biological effects of IL-1beta are therefore proportional to the ratio IL-1beta/IL-1ra. The coding regions of IL-1beta were examined for sequence variations by SSCP and sequencing after polymerase chain reaction (PCR) of genomic DNA. Three previously described polymorphisms (C(-511)-T, G(3877)-A and C(3954)-T) in the IL-1beta gene were determined by restriction fragment length polymorphism (RFLP) using Ava I, Aci I, and Taq I after PCR. The 86-base pair repeat polymorphism in IL-1ra was examined by PCR and electrophoresis and the T11100-C polymorphism in the IL-1ra gene was examined by RFLP using MspA1I after PCR. All polymorphisms were related to bone mass, biochemical markers of bone turnover, and presence of fracture in a study including 389 osteoporotic patients with vertebral fractures and normal controls. Two normal women were heterozygous for a shift from cytosine to thymine (C3263-T) in exon 4 of the IL-1beta gene. This substitution did not affect the amino acid sequence. We did not find other sequence variations in the IL-1beta gene apart from the already known polymorphisms. The distribution of C(-511)-T, G(3877)-A, and C(3954)-T genotypes was similar in the osteoporotic and the normal controls. No significant differences could be shown in bone mass or bone turnover. In the IL-1ra gene almost complete linkage was confirmed between the already known polymorphisms: G(1731)-A, G(1821)-A, A(1868)-G, G(1887)-C, T(8006)-C, C(8061)-T, 86 base pair variable number tandem repeat (VNTR), A(9589)-T, and a new polymorphism: T(1934)-C. The A1A1/A3 genotypes of the IL-1ra VNTR polymorphism were significantly more frequent in osteoporotic patients (56.2%) compared with age-matched normal controls (43.3%) (chi2 = 4.09; p = 0.043). The relative risk of osteoporotic fractures was increased to 1.68 (95% CI, 1.01-2.77) in individuals with A1A1/A3 genotypes. Bone mineral density (BMD) of the lumbar spine was reduced in individuals with A1A1/A3 genotypes (p = 0.014, analysis of variance [ANOVA]). The difference in bone mass between A1A1/A3 and A2A1/A2 tended to increase with increasing age. T1100-C genotypes were distributed similarly in osteoporotic patients and normal controls and the polymorphism was without effect on bone mass and biochemical markers of bone turnover. In conclusion, an 86-base pair repeat polymorphism in the IL-lra gene is associated with increased risk of osteoporotic fractures. Other polymorphisms in the IL-1ra and the IL-1beta genes are not associated with osteoporotic fractures or alterations in bone mass or bone turnover.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10750554     DOI: 10.1359/jbmr.2000.15.3.402

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  A strategy for identifying osteoporosis risk genes.

Authors:  David Rowe; Alexander Lichtler
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

2.  Relations between interleukin-1, its receptor antagonist gene polymorphism, and bone mineral density in postmenopausal Korean women.

Authors:  Jung Gu Kim; Kyung Sil Lim; Seung-Yup Ku; Seok Hyun Kim; Young Min Choi; Shin Yong Moon
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells.

Authors:  S K Baniwal; P K Shah; Y Shi; J H Haduong; Y A Declerck; Y Gabet; B Frenkel
Journal:  Osteoporos Int       Date:  2011-09-01       Impact factor: 4.507

4.  Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer.

Authors:  Ming-Hsui Tsai; Wen-Chi Chen; Chang-Hai Tsai; Liang-Wen Hang; Fuu-Jen Tsai
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

5.  Bone mineral mass is associated with interleukin 1 receptor autoantigen and TNF-alpha gene polymorphisms in post-menopausal Mediterranean women.

Authors:  R Fontova; C Gutiérrez; J Vendrell; M Broch; I Vendrell; I Simón; J M Fernández-Real; C Richart
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

6.  Cytokine production by whole blood cells: relationship to interleukin gene polymorphism and bone mass.

Authors:  Jung Gu Kim; Seung Yup Ku; Kyung Sil Lim; Byung Chul Jee; Chang Suk Suh; Seok Hyun Kim; Young Min Choi; Shin Yong Moon
Journal:  J Korean Med Sci       Date:  2005-12       Impact factor: 2.153

7.  Variable number of tandem repeat polymorphisms of the interleukin-1 receptor antagonist gene IL-1RN: a novel association with the athlete status.

Authors:  Sabina Cauci; Manuela Di Santolo; Kelli K Ryckman; Scott M Williams; Giuseppe Banfi
Journal:  BMC Med Genet       Date:  2010-02-22       Impact factor: 2.103

8.  Association of interleukin-1 beta (-511C/T) polymorphisms with osteoporosis in postmenopausal women.

Authors:  Tai-Hung Chao; Hsing-Ning Yu; Chi-Chuan Huang; Wen-Shen Liu; Ya-Wen Tsai; Wen-Tung Wu
Journal:  Ann Saudi Med       Date:  2010 Nov-Dec       Impact factor: 1.526

9.  Environmental factors and not genotype influence the plasma level of interleukin-1 receptor antagonist in normal individuals.

Authors:  H Cullup; P G Middleton; G Duggan; J S Conn; A M Dickinson
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 10.  Searching for genes underlying susceptibility to osteoporotic fracture: current progress and future prospect.

Authors:  S-F Lei; H Jiang; F-Y Deng; H-W Deng
Journal:  Osteoporos Int       Date:  2007-05-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.